Short answer
Elevance Health (ELV) filed its Q2 2026 10-Q quarterly report on Jul 15, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $50.5B (up 1.4% year over year) with net income of $1.5B.
Q2 2026 key financials · XBRL
- Revenue
- $50.5B
- +1.4% YoY · +0.6% QoQ
- Net income
- $1.5B
- −16.1% YoY · −17.1% QoQ
- Operating margin
- 3.5%
- EPS (diluted)
- $6.73
- −12.8% YoY · −15.9% QoQ
Source: XBRL data from the Elevance Health (ELV) Q2 2026 10-Q on SEC EDGAR. USD.
Elevance Health Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Segment performance figures not provided; four reportable segments identified
- Medical membership 44.9 million as of June 30, 2026
- Full-year 2026 results not necessarily indicative; no updated guidance or headwinds disclosed
Risk Factors
- No Risk Factors section provided; submitted text contains Items 2–6 only
- No new, updated, regulatory, operational, or competitive risks identifiable
- Repurchase-program authorization $5,337 million remaining as of June 30, 2026
- Three-month share repurchases totaled $234 million through June 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Elevance Health quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.